Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generic drug manufacturer Lannett Company has received approval from the FDA to market a copycat version of Gate Pharmaceuticals' obesity drug Adipex-P.
Subscribe to our email newsletter
The drug, phentermine hydrochloride, is approved for the short-term management of obesity. Lannett expects to commence marketing the product in June 2005.
Arthur Bedrosian, president of Lannett, was encouraged by the regulatory progress and explained that this would not be the only product the company expects to be releasing. “We currently have nine applications pending at the FDA and a number of other products in various stages of development that will further expand our product offering.”
According to NDC Health, the total US market for phentermine hydrochloride 37.5mg tablets is approximately $84 million. However, there are currently five other generic suppliers marketing this product.